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1. Introduction
Epithelial cells separate us from the external envi-
ronment, and separate di¡erent compartments within
our body. In order to cross intact epithelial and en-
dothelial cell sheets, molecules and cells have two
options: (1) go through cells (transcellular pathway)
or (2) go between cells (paracellular pathway). In
vertebrate organisms, the tight junction (TJ) is the
cellular structure which prevents the free passage of
molecules and cells through the paracellular path-
way, thereby ensuring the maintenance of composi-
tionally distinct body compartments. This ‘barrier’
function is essential in tissues, such as the brain,
where it is critical to maintain a tight separation
between blood vessels and interstitial £uids (blood-
brain barrier), but is also necessary in all epithelial
tissues involved in vectorial absorption and secretion.
A second function of TJ is to maintain a di¡erent
protein and lipid composition between the apical and
basolateral plasma membrane domains of polarized
epithelial cells (‘fence’ function). Excellent reviews in
recent years have discussed the structure, function
and regulation of TJ [1^7]. The reader is referred
0167-4889 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 8 ) 0 0 1 2 5 - 6
* Corresponding author;
E-mail : Sandra.Citi@molbio.unige.ch and citi@civ.bio.unipd.it
1 This review is dedicated to the memory of Thomas Kreis.
BBAMCR 14394 10-11-98
Biochimica et Biophysica Acta 1448 (1998) 1^11
to these reviews for areas which are not covered in
detail here.
Since the ¢rst discovery of a TJ-localized protein
in 1986 [8], many proteins have been shown to be
associated with TJ, either by direct immunoelectron
microscopic localization or by their physical or topo-
logical association with known TJ proteins (Table 1).
This minireview focuses on recent advances in the
identi¢cation and characterization of TJ proteins,
and how these advances may help to answer key
questions about TJ function and regulation.
2. Membrane proteins: occludin, claudins, and JAM
The membrane domain of TJ has a characteristic
ultrastructure. Transmission electron microscopy
shows focal sites of intimate contact between the
apposed plasma membranes of adjoining cells [9].
Freeze-fracture shows a fascinating network of ¢brils
(also called strands) and grooves on the two faces of
the fractured membranes, corresponding to the sites
of membrane apposition [10,11]. The ¢brils are
thought to be the structural counterpart of the bar-
rier function, and to contain molecules which form a
‘pore’ through which paracellular £ux occurs. For
some time, it was debated whether the ¢brils were
the result of a special con¢guration of lipids, or
whether they were proteinaceous in nature [12^14].
We now know, through the work of the Tsukita and
Dejana groups, that the TJ membrane domain con-
tains at least three distinct proteins, named occludin
[15], claudin [16], and JAM [17]. Occludin was iden-
ti¢ed by raising monoclonal antibodies against a
chicken liver junctional membrane fraction [15],
and claudin (actually two similar proteins, claudin-
1 and claudin-2) was identi¢ed by sequencing a Mr
22 kDa polypeptide present in the same membrane
fraction [16]. JAM was identi¢ed by raising mono-
clonal antibodies against endothelial cells [17]. Stud-
ies on these three molecules are starting to provide
answers to some important questions. Which pro-
teins form TJ ¢brils, and which are responsible for
Table 1
A list of TJ-associated proteins, with their apparent molecular
size (Mr) (kDa), and essential referencesa
Name Mr References
ZO-1 220^225 [8],[51,52]
Cingulin 140^160 [57]
BG9.1 192 [111]
ZO-2 160 kDa [49,53]
7H6 155^175 [61]
ZO-3 130 [19,50]
Occludin 58^82 [15,30]
Rab8 24 [112]
Rab13 41 [39]
Rab3B 25 [38]
Symplekin 150 [43]
Protein kinase Cj 81 [36]
G protein K 39^41 [36,37]
19B1 210 [65]
AF-6 180^195 [67]
Claudins 22 [16]
JAM 36^41 [17]
aSee text for additional references. The variability in apparent
molecular size of some TJ proteins is due to tissue- or species-
speci¢c variations, and in some cases (for example occludin)
can also depend on phosphorylation levels.
C
Fig. 1. A schematic representation of TJ, with emphasis on pro-
teins of the TJ membrane domain. (A) Claudin(s) (light gray)
and occludin (dark gray) are depicted as chains with four trans-
membrane regions embedded in the plasma membrane. JAM is
depicted as a protein with one transmembrane domain. The
plasma membranes of adjoining cells (Cell-1 and Cell-2) are
schematically represented and de¢ne the paracellular pathway
(extracellular space). The N-terminal and C-terminal ends of oc-
cludin, claudin and JAM are indicated with N and C, respec-
tively. The C-terminal domain of occludin interacts with cyto-
plasmic plaque components of TJ (ZO-1 and ZO-3), whereas
nothing is known yet on cytoplasmic interactions of claudin(s)
and JAM. ZO-1, ZO-2 and ZO-3 are shown as a complex. ZO-
1 and AF-6 interact one with the other and with actin. (B)
Four hypothetical modes of polymerization of claudin(s) and
occludin. (1) Homopolymerization of claudin(s) and homotypic
interaction with claudin(s) of adjoining cell. (2) Homopolymeri-
zation of occludin, and homotypic interaction with occludin of
adjoining cell. (3) Heteropolymerization of claudin(s) and occlu-
din, and homotypic interactions with identical molecules of ad-
joining cell. (4) Heteropolymerization of claudin(s) and occlu-
din, and heterotypic interactions with di¡erent molecules of
adjoining cell. Also note that (a) and (b) in each panel refers to
hypothetical alternative ways of homophylic and heterophylic
interactions between the extracellular loops of claudins and oc-
cludin. (a) extracellular loop-1 associates with extracellular
loop-2 of opposing molecule; (b) extracellular loop-1 associates
with extracellular loop-1 of opposing molecule. The shapes and
sizes of the proteins are imaginary and out of scale, and other
TJ proteins of the plaque domain (Table 1) have been omitted
for clarity.
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the barrier function of TJ? Are the membrane pro-
teins of TJ involved in homotypic cell-cell adhesion?
Characterization of the predicted tertiary structure
of occludin, claudin and JAM provides clues to
understanding their organization in the TJ mem-
brane. Occludin and claudin share a common mem-
brane topology, with four major putative transmem-
brane domains, whereas JAM shows only one
putative transmembrane sequence (Fig. 1A). The
transmembrane domains of occludin and claudin
are separated by hydrophilic regions, which are be-
lieved to form one cytoplasmic loop and two extra-
cellular loops. In addition, occludin contains a hy-
drophilic N-terminal region of 60 residues, and a
hydrophilic C-terminal region of about 250 residues,
which are believed to be exposed on the cytoplasmic
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side of the junctional membrane [15] (Fig. 1). The C-
terminal domain of occludin may be important in
anchoring it to the cytoplasmic plaque domain of
TJ, through the interaction with proteins such as
ZO-1 [18] and ZO-3 [19] (Fig. 1A), and mediating
basolateral targeting [20]. Claudin contains a short
(20^40 amino acids, depending on the claudin iso-
form) C-terminal domain [16], and JAM shows a
putative intracellular domain of 45 residues [17].
The extracellular portion of JAM (215 residues) con-
tains two domains with intrachain disul¢de bonds
typical of immunoglobulin-like loops of the V type
[17] (Fig. 1A).
Immunolabeling of freeze-fracture replicas of nor-
mal or transfected cells shows that occludin and clau-
din are components of TJ ¢brils [16,21], whereas
similar studies have not been performed yet with
JAM. Only claudin appears to induce the formation
of a developed network of TJ ¢brils in the plasma
membrane of transfected L-cells [113], which is pos-
sibly the ultimate test to determine whether a TJ
membrane protein actually forms the ¢brils. These
results allowed Tsukita’s group to formulate the hy-
pothesis that TJ ¢brils are assembled by a process
similar to that of intermediate ¢lament assembly,
whereby several proteins (occludin, claudin, others?)
sharing a common structural motif (for example, the
four transmembrane domains) can give rise to a sim-
ilar polymer embedded in the plasma membrane [16].
To test this model it is necessary to address a number
of questions. First, what moieties of the claudin and
occludin molecules are involved in the polymeriza-
tion process (Fig. 1B)? It was shown that occludins
from di¡erent species can oligomerize in vivo [22],
and C-terminal truncations of exogenous occludin
are targeted to TJ [22,23], suggesting that the C-ter-
minal domain is not involved in occludin polymer-
ization. On the other hand, the four transmembrane
domains do not appear to be su⁄cient to act as
structural motifs for TJ assembly, since other mem-
brane proteins, such as connexins, have four trans-
membrane domains but do not accumulate in TJ.
Second, can occludin in one cell form heteropoly-
mers with claudin in the same cell and interact het-
erotypically with claudin on the adjoining cell (Fig.
1B)? Occludin behaves as a cell-cell adhesion mole-
cule [24], and transfection of truncated occludin in-
duces redistribution of occludin in neighboring cells
[23], suggesting that the extracellular domains of oc-
cludin on adjoining cells somehow interact. How-
ever, it is not clear whether occludin interacts later-
ally with claudin molecules, or whether it can
interact with claudin on an opposing cell (Fig. 1B).
JAM has also been reported to mediate homotypic
cell-cell adhesion [17].
The organization of the ¢bril polymer within one
cell and its association with the polymer of the ad-
joining cell is probably at the core of TJ barrier
function. Indeed, a perturbation of the occludin-con-
taining polymer has e¡ects on the barrier and fence
properties of TJ, as shown by the observation that
heterologous expression of truncated occludin results
in an increase in transepithelial resistance and loss of
the fence function in cultured MDCK cells [23,25]
and in a decreased barrier function in Xenopus em-
bryos [22]. In addition, peptides mimicking the se-
quence of the second extracellular loop of chicken
occludin decrease transepithelial resistance in Xeno-
pus A6 cells [26]. All these observations suggest that
occludin is important for the barrier function of TJ.
However, recent knockout experiments in mouse em-
bryonic stem cells have demonstrated that occludin is
not necessary to form functionally competent TJ [27].
In fact, occludin-de¢cient epithelial cells show nor-
mal polarity, normal number and morphology of TJ
¢brils, normal localization of ZO-1, and normal dif-
fusional barrier to a labelled tracer [27]. This raises
the possibility that occludin is not a key component
of TJ ¢brils, nor does it have a critical role in the
barrier function of TJ, and in anchoring the mem-
brane domain of TJ to the plaque domain. So, is
occludin a redundant protein, and are all of these
functions performed by claudin and JAM? While
further transfection and knockout studies are being
carried out, it is interesting to note that when JAM is
transfected into CHO cells, the permeability of a cell
monolayer to dextran is decreased by 50% [17]. Since
dextran is a large molecule (Mr 38 900) and the same
e¡ect is produced by transfection of cadherins [17], it
remains unclear whether JAM could form structures
capable of forming a barrier to the £ux of ions and
small solutes. In principle, the homotypic interaction
of JAM molecules on adjoining cell membranes may
contribute to regulating the passage of large mole-
cules and cells through endothelial sheets. Indeed,
the observation that an anti-JAM monoclonal anti-
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body inhibits transendothelial migration of mono-
cytes in vitro and in vivo suggests that JAM may
actually bind to and direct the migration of mono-
cytes through the intercellular cleft [17].
The identi¢cation of multiple TJ membrane pro-
teins may provide better tools to address an old
problem: what is the relationship between the barrier
function of TJ, which is extremely heterogeneous in
di¡erent tissues and cell types [28], and the molecular
composition of TJ? The ¢rst issue is to determine
whether the tissue distribution of occludin, claudins
and JAM parallels that of TJ. This seems to be the
case for occludin, which is expressed only in TJ-bear-
ing epithelial and endothelial cells [15,29]. On the
other hand, claudin is expressed also in skeletal
muscle [16], and JAM is expressed in megakaryocytes
[17], which lack TJ. The role of claudin and JAM in
tissues lacking TJ remains unclear. It is also unclear
why JAM expression is low or absent in hepatocytes,
which contain well-characterized TJ [17]. The second
issue to determine is whether di¡erent isoforms of TJ
membrane proteins show tissue-speci¢c expression.
This seems to be the case only for claudin, of which
there are at least two isoforms (claudin-1 and clau-
din-2) with di¡erent tissue distribution [16], whereas
no isoforms have been reported for occludin and
JAM.
It is interesting that despite the similarity in mem-
brane topology, occludin and claudin do not show
any homology at the amino acid sequence level. This
would suggest that they have evolved from unrelated
precursor proteins. If occludin function is redundant
with respect to claudins, one could speculate that
occludin may have appeared later in evolution, to
provide some accessory function. However, it is un-
clear how phylogenetically ancient occludin and clau-
din are, and how the evolution of TJ morphology
correlates with the expression of these proteins or
their homologous counterparts in invertebrates or
early vertebrates. Some information about evolution-
ary conservation of occludin is available. Occludin
has been detected and sequenced from chicken,
mouse, human, rat kangaroo, dog [15,30] and Xen-
opus laevis (Cordenonsi et al., in preparation). Its
sequence is relatively well conserved across mamma-
lian species, but diverges signi¢cantly from that of
chicken [30] and Xenopus (Cordenonsi et al., in prep-
aration). Claudins from human and mouse are al-
most 100% identical, but nothing is known so far
about their expression and sequence in other organ-
Fig. 2. Multiple alignement of the amino acid sequences of human Clostridium perfringens enterotoxin receptor (hCPE-R; accession
number AB000712), human androgen withdrawal apoptosis protein (hRVP-1, accession number AB00714), transmembrane protein de-
leted in velo-cardio-facial syndrome (hTMVCF; accession number AF000959), mouse brain endothelial cell protein BEC1 (MBEC1;
accession number AF035814), and mouse claudin-1 and claudin-2 (mCLAUDIN-1, mCLAUDIN-2, [16]).
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isms. Occludin amino acid sequence does not show
homology to know proteins, whereas claudins (clau-
din-1 and claudin-2) are homologous to a family of
four transmembrane domain proteins, including the
rat androgen withdrawal apoptosis protein (RVP-1)
[31], the transmembrane protein deleted in velo-car-
dio-facial syndrome (TMVCF) [32], the Clostridium
perfringens enterotoxin receptor (CPE-R) [33,34],
and the brain endothelial cell protein BEC1 [35]
(Fig. 2).
It is likely that the discovery of occludin, claudins
and JAM is not the end of the story of TJ membrane
proteins. For example, the chicken liver junctional
fraction used by Tsukita’s laboratory to identify oc-
cludin and claudin contains an additional eight poly-
peptides which remain to be characterized [16].
3. Cytoplasmic plaque proteins: linking membrane to
cytoskeleton?
Except for occludin, claudins and JAM, all TJ
proteins identi¢ed so far (Table 1) are localized in
the cytoplasmic plaque domain of TJ. These include
the MAGUK proteins of TJ, called ZO-1, ZO-2, and
ZO-3, and a more heterogeneous group, including
cingulin, symplekin, 19B1, and AF-6. Finally, the
cytoplasmic plaque domain of TJ contains proteins
involved in signal transduction pathways, such as
protein kinases [36], heterotrimeric G proteins
[36,37], and small GTP-binding proteins [38,39].
These latter proteins are not uniquely localized at
TJ, but their role in the assembly and functional
modulation of TJ may be critical. The possible roles
of these signaling proteins in TJ assembly have been
reviewed recently [40] and will not be discussed here.
Several of the proteins of the cytoplasmic plaque
domain of TJ are not exclusively expressed in TJ-
bearing cells. For example, ZO-1 and symplekin are
expressed in ¢broblasts and neurons [41^43]. ZO-1
exists in two isoforms (ZO-1 K+ and ZO-1 K3)
which are di¡erentially expressed in tissues showing
a di¡erent degree of TJ ‘plasticity’ [44] and show a
sequential expression during early mouse develop-
ment [45]. ZO-1 [46], symplekin [43] and cingulin
[47] can show a nuclear immuno£uorescent localiza-
tion, depending on various factors, including degree
of con£uency of the epithelial monolayer, cell type,
and ¢xation procedure. For example, symplekin is
localized in the nucleus in non-epithelial cells, and
is localized in TJ and in the nucleus in epithelial cells
[43]. The signi¢cance of the nuclear localization of TJ
proteins is unclear. A possible model could predict
that TJ plaque proteins exist in a junction-associated
(less soluble) pool in equilibrium with a cytoplasmic
(more soluble) pool, and when the equilibrium is
shifted towards the soluble pool there is nuclear ac-
cumulation of the protein. Whether nuclear TJ pro-
teins may lead to changes in gene expression, simi-
larly to what has been shown for L-catenin [48],
remains to be seen.
ZO-1, ZO-2 and ZO-3 form a complex on the
cytoplasmic side of TJ, and indeed ZO-2 and ZO-3
were ¢rst identi¢ed as polypeptides present in ZO-1
immunoprecipitates [49,50]. Sequence analysis shows
that ZO-1, ZO-2 and ZO-3 are related, and are mem-
bers of the large family of membrane-associated
guanylate kinase (MAGUK) proteins [19,51^53].
MAGUK proteins share several structural motifs,
including a varying number (typically 1^3) of PDZ
domains (also called GLGL/DHR), one src homol-
ogy 3 (SH3) region, and one guanylate kinase
(GUK) homology region [54]. The PDZ domain
has been shown to bind to speci¢c sequences at the
C-termini of proteins [55], to be involved in the clus-
tering of membrane channels/receptors [56], and to
mediate association with other proteins containing a
PDZ domain [54]. The SH3 region and the GUK
homology region may also involved in interactions
with other proteins.
Cingulin was identi¢ed by monoclonal antibodies
raised against a myosin-enriched fraction of chicken
intestinal epithelial cells [57], and has been detected
only in TJ-bearing epithelial and endothelial cells
[58,59]. Cingulin contains a Mr 108 kDa region
with biochemical and physical properties of a
coiled-coil dimer [57,58]. Cloning of cingulin cDNA
shows that the coiled-coil domain is similar to the
coiled-coil regions of myosin heavy chains [60]. In
addition to the coiled-coil region, cingulin contains
a N-terminal globular region with no signi¢cant ho-
mology to other known proteins (Cordenonsi et al.,
in preparation). The observation that cingulin co-
puri¢es with actomyosin [58] suggests that cingulin
may link the TJ plaque to the actomyosin cyto-
skeleton. This hypothesis is supported by in vitro
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binding experiments, indicating that cingulin inter-
acts with other TJ proteins and components of the
actomyosin cytoskeleton (Cordenonsi et al., in prep-
aration).
Another group of TJ plaque protein comprises
7H6, symplekin and 19B1 and AF-6. 7H6 was iden-
ti¢ed by raising monoclonal antibodies to a rat liver
junctional fraction [61]. 7H6 is a phosphoprotein,
and its expression has been studied in normal and
cancerous epithelial cells and tissues [62^64]. Symple-
kin is expressed in epithelial cells, where it is local-
ized in TJ, and in non-epithelial cells, where it is
localized in the nucleus [43]. Symplekin sequence
shows no homologies to other proteins in databases
[43]. 19B1 is co-localized with ZO-1 in cultured Xen-
opus A-6 cells [65], and is detected as a maternal
protein in early development of Xenopus laevis [66].
AF-6 co-localizes with ZO-1 in cultured epithelial
cells [67], and was originally identi¢ed as the fusion
partner of the human acute lymphoblastic leukemia-
1 (ALL-1) protein [68,69]. The deduced amino acid
sequence of AF-6 shows one PDZ domain, two Ras-
binding domains, and one myosin V- and one kine-
sin-like cargo-binding domains [69].
Recent studies have begun to clarify the molecular
interactions occurring between some of the TJ pro-
teins described above (see also Fig. 1A). The C-ter-
minal domain of occludin binds ZO-1 and ZO-3,
based on GST pull-down assays and direct interac-
tion studies [18,19] (Fig. 1A). Pull-down assays also
show that occludin binds ZO-2, although it is not
clear whether this interaction is direct, or mediated
by ZO-1 [18]. ZO-1 interacts with the Ras-binding
domain of AF-6, and this interaction is inhibited
by activated Ras [67]. In vitro experiments also
show that ZO-1 is associated with catenins [70,71].
This latter observation is particularly interesting, in
view of the ¢nding that in cells devoid of TJ, such as
¢broblasts, ZO-1 is localized at cadherin-dependent
adhesion sites [41,42,72]. Thus, it can be envisaged
that during epithelial polarization ZO-1 may initially
form a complex with the cadherin-based multiprotein
complex, and then becomes predominantly localized
at TJ only when it is recruited there by TJ-speci¢c
protein(s). Taken together, this evidence suggests
that ZO-1 is at the center of a network of protein-
protein interactions, and may be critical in recruiting
proteins necessary to establish TJ and in mediating
signal transduction events. However, the precise
function of ZO-1 in the TJ is not known, nor is it
known whether ZO-2 and ZO-3 play a functionally
redundant role, or have functions which are comple-
mentary to or distinct from those of ZO-1.
4. The actin cytoskeleton: more muscle, less barrier?
Actin micro¢laments have been localized near the
cytoplasmic surface of TJ by electron microscopic
techniques [73,74]. In addition, actin micro¢laments
and associated proteins are abundant in a thick cir-
cumferential ring associated with the zonulae adhaer-
entes [75], immediately beneath TJ. There is a vast
literature documenting the possible roles of the actin
cytoskeleton in the modulation of TJ function (re-
viewed in [76]). Most of these studies are based on
a pharmacological approach, whereby cultured or
native epithelial cells are treated with agents which
perturb the organization or contractility of the acto-
myosin cytoskeleton. Such agents include phalloidin
[77], cytochalasins [78,79], protein kinase inhibitors
and activators [50,80^86], toxins [87], Rho proteins
[88,89], and myosin light chain kinase [90]. All of
these agents in£uence TJ barrier function, as assayed
by transepithelial resistance and tracer £ux studies,
and in some cases they also produce changes in TJ
ultrastructure and distribution of TJ proteins.
Although it is di⁄cult to establish whether these
agents may have direct e¡ects on TJ proteins, it ap-
pears that all the agents that increase the contractil-
ity of the actomyosin cytoskeleton, for example by
inducing stress ¢ber formation [80,91] or increasing
myosin light chain phosphorylation [90], cause a de-
crease in the barrier function of TJ (increased perme-
ability). Vice versa, the agents which negatively a¡ect
the contractility of the actomyosin cytoskeleton pro-
tect cell monolayers from a fall in the barrier func-
tion caused by other treatments (see for example
[83,92]). These observations support a model where-
by cortical tension generated by the perijunctional
actomyosin cytoskeleton physiologically regulates
the permeability of TJ (Fig. 3). Under normal cir-
cumstances, TJ are subjected to a ‘tonic’ contraction
(Fig. 3A). When the contractility of the circumferen-
tial actomyosin ring increases, the tension which is
generated induces adjacent cells to pull apart at the
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level of the junctional complex, and reduces TJ bar-
rier (Fig. 3B). Vice versa, a relaxation with respect to
the normal ‘tonic’ state of tension induces a closing
of the TJ pore and an increased barrier function
(Fig. 3C).
To test the model above, and to understand at the
molecular level how the contractility of junctional
actomyosin may in£uence TJ, it is critical to deter-
mine which TJ proteins bind to actin or actin-asso-
ciated proteins. This area of work is still in its in-
fancy. It was recently shown that a C-terminal
fragment of ZO-1 cosediments with F-actin [71]. In
addition, ZO-1 interaction with catenins [70,71] pro-
vides another indirect link to the junction-associated
actomyosin cytoskeleton. Another TJ protein which
may provide a link to the actin cytoskeleton is AF-6,
since the rat homolog of AF-6, called afadin, has
been characterized as a junctional protein containing
an F-actin-binding region [93].
The interaction of TJ proteins with the cytoskele-
ton is interesting to study not only because circum-
ferential contraction of actomyosin may modulate TJ
permeability, but also because cytoskeletal interac-
tions may contribute to forming the TJ ‘fence’, which
restricts the mobility and distribution of polarized
membrane molecules. This function may be carried
out not only by the actomyosin cytoskeleton, but
also by the spectrin/fodrin cytoskeleton [94]. In this
respect, it is noteworthy that ZO-1 has been reported
to interact with spectrin in vitro [18,41,95].
The interaction between TJ proteins and the acto-
myosin cytoskeleton may be a primary target for
physiological or pathological signals. If the model
illustrated in Fig. 3 is true, one would predict that
any event which would reduce or abolish the inter-
action of the TJ plaque with the actomyosin cytos-
keleton would cause an increase in the barrier func-
tion of the epithelium. Vice versa, any event which
may strengthen the anchorage of the TJ plaque to
the contracting cytoskeleton would reduce TJ barrier
function. This hypothesis is currently being tested by
a number of laboratories using a number of ap-
proaches, including the exogenous expression of TJ
proteins fragments in cultured epithelial cells.
5. Protein phosphorylation: a molecular switch to
control TJ assembly?
Occludin is phosphorylated on Ser and Thr resi-
dues [96,97], and occludin phosphorylation/dephos-
phorylation has been implicated in the biogenesis
of TJ in cultured MDCK cells [96,98] and in Xenopus
laevis embryos [97]. Using monoclonal antibodies
which distinguish between the more phosphorylated
and less phosphorylated forms of occludin, it was
Fig. 3. A schematic representation of how the contraction of the junctional actomyosin ring might regulate the barrier function of TJ.
Only the junctional region between two cells is shown in the diagram. Mechanical force pulling the TJ membrane centripetally is rep-
resented by oblique arrows on the intracellular side of the TJ. Vertical arrowheads indicate the solute £ux through the paracellular
pathway.
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shown that increased phosphorylation correlated
with (a) decreased extractability of occludin, and
(b) TJ assembly by calcium switch [96]. It was thus
suggested that occludin phosphorylation is a key step
in TJ assembly [96]. The role of phosphorylation
may be di¡erent in early embryogenesis of Xenopus
laevis. In this system, a progressive dephosphoryla-
tion-dependent downshift in electrophoretic mobility
of occludin was observed during the course of devel-
opment from unfertilized eggs to gastrula stage em-
bryos [97]. The early stages of embryogenesis are
correlated with de novo TJ assembly between Xeno-
pus blastomeres, as shown by morphological and
functional assays [66,99^101]. Thus, occludin de-
phosphorylation, rather than phosphorylation, ap-
pears correlated with TJ assembly during early Xen-
opus development. It is not clear why
phosphorylation may play an opposite role in cul-
tured MDCK cells and Xenopus embryos. One pos-
sibility is that de novo biogenesis of junctions in
embryos occurs in a distinct fashion from that of
MDCK cells in low calcium. It is also possible that
there are multiple occludin phosphorylation sites, not
all of which in£uence electrophoretic mobility, or
that there are maternal and zygotic Xenopus occludin
isoforms, which behave di¡erently. One approach to
resolve this apparent discrepancy will be to deter-
mine the in vivo phosphorylation sites of occludin
and carry out experiments with mutated molecules.
Except for occludin, it is unclear whether phos-
phorylation of other TJ proteins is related to TJ
assembly. ZO-1 and ZO-2 are phosphorylated [102].
ZO-1 is phosphorylated on Ser residues [102], and
can be phosphorylated on Tyr residues in cells
treated with activators of tyrosine protein kinases
or inhibitors of tyrosine protein phosphatases [103^
106]. Cingulin is phosphorylated on Ser residues [91].
Changes in total ZO-1 phosphorylation may be cor-
related with alterations in its distribution [107], but
no clear correlation has been established yet between
ZO-1 [50,108,109] or cingulin [91] phosphorylation
and TJ function. Interestingly, the SH3 domain of
ZO-1 binds in vitro to a serine protein kinase that
phosphorylates a region immediately C-terminal to
this domain [110].
In summary, phosphorylation is an attractive
mechanism by which TJ proteins might be regulated
in order to coordinate TJ assembly or modulate TJ
function. However, since occludin, the only protein
for which a clear correlation between level of phos-
phorylation and TJ assembly has been observed, is
not necessary for TJ [27], the e¡ective signi¢cance of
TJ protein phosphorylation remains to be demon-
strated.
6. Future perspectives
In the last few years, the progress in the identi¢-
cation of TJ proteins and in the characterization of
their interactions has been quite remarkable. Despite
this progress, the function of essentially all TJ pro-
teins is unknown, and the precise molecular mecha-
nisms by which epithelial and endothelial cells estab-
lish, maintain and modulate the paracellular
permeability barrier remain elusive. The coming
years will witness the publication of more studies
investigating the roles of known and novel TJ pro-
teins by up- or down-regulation in cultured cells or
living animals. These studies, and the further charac-
terization of interactions among TJ proteins and be-
tween TJ proteins and the cytoskeleton, will provide
much useful information. Ultimately, the targeted
disruption of TJ proteins in vertebrate animal sys-
tems will be necessary to determine which proteins
are necessary and su⁄cient to form a functional TJ.
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